Event

Manuel Quaresma

PharmD
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial and Rare ;Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial

Craig S. Conoscenti

M.D.
Boehringer Ingelheim Pharmaceuticals Inc;Boehringer Ingelheim Pharmaceuticals Inc.

Loaiza Loaiza

M.D.
Boehringer Ingelheim Pharma GmbH & Co. KG

Paul Hernandez

MDCM, FRCPC
Dalhousie Univ;Dalhousie University;QEII Health Sciences Centre

Lisa Hood. Lancaster

M.D.
Vanderbilt Univ Medical Ctr;Vanderbilt University;Vanderbilt University Medical Center

Susanne Stowasser

M.D.
Boehringer Ingelheim Pharma GmbH & Co. KG

Yoshikazu Inoue

MD, PhD
Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center;NHO Kinki-Chuo Chest Medical Center

Luca Richeldi

MD, PhD
Catholic University of the Sacred Heart;Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli

Daniel Wachtlin

MSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis (IPF): Pooled Data from Six Clinical Trials